Harnessing the Immense Clinical Potential of Targeted Intracellular Delivery
Ligand-free dendrimer medicines that find diseased cells on their own, across the blood-brain barrier, for CNS, retinal, and inflammatory diseases.
Publications
Disease Models
Primates
6 Ph1 · 2 Ph2
via Ashvattha Therapeutics
& Pending
Where would you like to start?
Four dendrimer platforms
Hydroxyl PAMAM, glucose dendrimers, antibody conjugates, and drug conjugates for brain and eye.
See the science PeopleMeet the lab
Our PIs, postdocs, and students, plus alumni and life in the lab.
Meet the team TranslationFrom lab to patient
Two Hopkins spin-outs and eight clinical trials, all positive to date.
See our impact JoinWork with us
Openings for students and postdocs, and partnership inquiries.
Get in touchDisease-Directed Nanomedicine
The Kannan Labs at the Center for Nanomedicine, Johns Hopkins University, is a world-leading group in dendrimer-based therapeutics. Dendrimers possess the highest surface functional density of all nanomaterials, a property that enables them to interact with disease pathology and disease cells in unique, unexpected ways.
We develop scalable, ligand-free, cell-targeted treatments for long-standing challenges: overcoming the blood-brain barrier, non-viral gene and gene-editing delivery, oral obesity treatments, intracellular antibody delivery, systemic retinal treatments, and more.
Two decades of foundational discovery, validated in over 60 models across six species including primates, has translated into multiple successful clinical trials and JHU spin-out companies with over $120 million in venture funding.
See Our ResearchLigand-Free Cell Targeting
Dendrimers find diseased cells without targeting ligands, guided by disease pathology and injury extent alone.
Scalable DDC Platforms
Dendrimer-drug conjugates are modular, scalable, and cleared intact through the kidney with minimal off-target effects.
Clinical Translation
Positive Phase 2 outcomes in COVID-19, wet AMD, and DME, with active programs at two JHU spin-outs.
Unmet Medical Needs
BBB crossing, neuroinflammation, retinal disorders, epilepsy, and TBI, where patients need new options most.
Our Science
Four dendrimer platforms, each built around a delivery problem that conventional drugs cannot solve.
Meet the Lab
Engineers, chemists, clinicians, and biologists working on one problem: getting medicines to the right cells. Click any card for the full profile.
A chemical engineer with a PhD from Caltech, Prof. Kannan has pioneered dendrimer nanomedicine for over 20 years at Johns Hopkins. His group discovered that hydroxyl PAMAM dendrimers selectively target reactive microglia and macrophages in disease, validated in over 60 models across six species including primates. He is an author of more than 190 patents and co-founded Ashvattha and Samata Therapeutics.
Research Associates
1 associatePostdoctoral Researchers
9 researchersGraduate Students
2 studentsUndergraduate Students
1 studentGallery
Lab events & outings
Research microscopy & imaging
Inside the Kannan Labs
Two decades of dendrimer science, one bench at a time.
Chemistry to clinic
Few labs make the material, test it in disease models, and see it reach patients. Our dendrimers have gone from synthesis to Phase 2 trials, and students here work at every stage of that path.
Validated, then validated again
A targeting result counts once it holds up across models and species. That habit is how the hydroxyl dendrimer platform was confirmed in more than 60 models before it went to the clinic.
Built on partnerships
Our projects run with clinicians and scientists across Wilmer, Kennedy Krieger, and the wider Hopkins campus, and with our spin-out companies. Most papers here have co-authors from more than one department.
Training & growth
New members learn dendrimer synthesis and characterization, in vitro and in vivo testing, and imaging, then take ownership of a project of their own. Presenting at conferences such as CRS is part of the job.
Former lab members now run their own labs, lead R&D teams in industry, and work at our spin-outs.
Selected Work
From Lab to Patient
The robustness and scalability of our DDCs has enabled significant clinical translation, with two JHU spin-out companies advancing therapies through clinical trials.
People with wet AMD and diabetic macular edema often need injections into the eye every month or two, for years. Many inflammation-driven diseases of the brain and eye have no treatment that reaches the cells causing the damage.
Co-founded by Drs. Kannan and Sujatha Kannan, Ashvattha advances clinical-stage nanomedicine that traverses tissue barriers to selectively target activated cells in inflammation, across ophthalmology, neurology, and inflammation.
More than $120 million raised and 6 Phase 1 and 2 Phase 2 trials, all positive. Phase 2 results include a 67% reduction in intravitreal injection need for wet AMD and DME patients.
All Positive
Cannabinoids and psychedelics show promise for epilepsy, pain, and depression, but they act on healthy brain cells too, and those side effects limit how they can be used.
Co-founded by Drs. Kannan Rangaramanujam, Sujatha Kannan, and Kunal Parikh, Samata builds dendrimer-drug conjugates of cannabinoids and psychedelics that concentrate in the brain cells driving disease.
Lasting relief for epilepsy, pain, depression, and more, without the systemic side effects of the free drug.
Areas
at Hopkins
From the Lab
Destiny, Discovery, and Daring Intuition: Dr. Kannan Rangaramanujam on the Future of Translational Nanomedicine
From a rural village in South India to leading groundbreaking nanomedicine at Johns Hopkins, a story shaped by resilience, intuition, and purpose. His pioneering work has the potential to revolutionize treatments for ocular, neurological, and inflammatory diseases.
Read the story →Ashvattha Reports Positive 40-Week Phase 2 Results for Migaldendranib in DME & nAMD
End-of-study results show migaldendranib is safe, well-tolerated, and delivers marked improvements in efficacy with reduced need for intravitreal injections.
Read the release →Hopkins Researchers Develop COVID-19 Nanomedicine: Promising Phase 2 Results
Johns Hopkins husband-and-wife researchers develop a dendrimer nanomedicine for severe COVID-19, with stunning Phase 2 results and personal stakes for the Kannan family.
Read the story →Dedication of the Arnall Patz Distinguished Professorship
Prof. Kannan received the Arnall Patz Distinguished Professorship at the Wilmer Eye Institute, speaking on nanotechnology-based targeted drug delivery for inflammation-driven diseases.
Read more →Wilmer Celebrates 100 Years: Kannan Lab's Precision Nanomedicine Featured
Phase IIa results showing 67% reduction in intravitreal injection need highlighted in Wilmer's centennial. A subcutaneous treatment with a systemic bilateral effect, a "stunning proof of concept."
Read more →Work With Us
Prospective students, postdocs, visiting scientists, and industry collaborators are encouraged to reach out.
Prospective students & postdocs
We take PhD rotation students, postdocs, visiting scholars, and undergraduates. Send your CV and a few lines on which of our platforms you'd want to work on.
Email Prof. KannanPartnerships
Clinicians, academic groups, and companies with a disease where getting the drug to the right cell is the bottleneck. We're glad to talk about dendrimer approaches.
Start the conversationGet in Touch
Please include your CV and a brief statement of research interest when reaching out.
Baltimore, Maryland 21231-1104
Johns Hopkins University
Wilmer Eye Institute · JHU School of Medicine
Find Us Online
Prospective Lab Members
Fill out the form and your message will open in your email client addressed to Prof. Kannan.
→ Clicking Send will open your email client pre-filled to krangar1@jhmi.edu